Venmax Drugs Approves Unaudited Q1 FY27 Results; Forfeits Warrants

Venmax Drugs and Pharmaceuticals Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the forfeiture of 7,80,001 partly paid-up Convertible Share Warrants. These warrants were originally allotted on March 20, 2025, at an issue price of ₹20/- each. The forfeiture is due to the non-payment of the balance subscription amount of ₹15/- per warrant by the holders. Consequently, the upfront subscription amount of ₹5/- per warrant, totaling ₹39,00,005/-, has been forfeited and retained by the company.